Macrophage Therapeutics to Present at BIO2015 Conference
June 15 2015 - 7:30AM
Business Wire
Macrophage Therapeutics, Inc. a subsidiary of Navidea
Biopharmaceuticals, Inc. (NYSE MKT:NAVB), announces that James
Goldschmidt, Ph.D., Macrophage Therapeutics’ Chief Operating
Officer, will present at the Biotechnology Industry Organization
(BIO) 2015 International Convention on Tuesday, June 16, 2015, at
3:00 p.m. EDT in Theater 1. The conference will be held at The
Pennsylvania Convention Center (June 15-18, 2015, Philadelphia,
PA).
A live webcast of Dr. Goldschmidt’s presentation can be accessed
at the following URL:
http://www.veracast.com/webcasts/bio/internationalconvention2015/13114156672.cfm.
An archived version of the webcast will be available and can be
accessed within the Investors' section of the Navidea website
at www.navidea.com.
About Macrophage Therapeutics, Inc.
Macrophage Therapeutics, Inc., a newly created subsidiary of
Navidea Biopharmaceuticals, Inc. (NAVB), is developing therapeutics
using the patented Manocept™ immunotherapy platform licensed from
Navidea to target over-active macrophages implicated in cancer,
cardiovascular, central nervous system, autoimmune, antiviral, and
skin diseases. Manocept specifically targets CD206, or mannose
receptor prevalent on over-active macrophages. The technology
enables highly specific targeted delivery of active (either
existing or yet to be developed) agents that can modulate the
activity of over-active macrophages that have been implicated in
many diseases. Targeted delivery should significantly enhance a
given compound’s efficacy and safety. For more information, please
visit the Company's web site at www.macrophagetherapeutics.com
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics, and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150615005685/en/
Navidea BiopharmaceuticalsInvestorsTom Baker,
617-532-0624tbaker@navidea.comorMediaSharon Correia, 978-655-2686Associate
Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024